MT-5

MT-5 is an experimental **small-molecule mTOR inhibitor** with a **quinoline scaffold** identified by virtual screening from the ChemDiv database and reported in preclinical oncology research. It inhibits mechanistic target of rapamycin signaling, showing in vitro kinase inhibitory activity against mTOR and antiproliferative effects across multiple cancer cell lines, with particularly notable activity in HCT-116 human colorectal cancer cells. Published work describes effects on cell migration, cell-cycle arrest, and apoptosis in colorectal cancer models, along with favorable in vitro stability in artificial gastrointestinal fluids, rat plasma, and liver microsomes. MT-5 appears to be a research-stage lead compound rather than a clinically developed commercial asset, with no clear evidence from the provided source of formal company-sponsored clinical development, branding, or manufacturing.